Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Timothy A. Yap; Erika Hamilton; Todd Bauer; Ecaterina E. Dumbrava; Rinath Jeselsohn; Aaron Enke; Sabrina Hurley; Kevin K. Lin; Jenn Habeck; Heidi Giordano; Geoffrey I. Shapiro

Journal ArticleOPEN ACCESS

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Yap T
Hamilton E
Bauer T
et al.

JCO Precision Oncology (2022) (6)

DOI: 10.1200/po.21.00456

37Citations

21Readers

Abstract

Promising activity of rucaparib + sacituzumab govitecan in pts with solid tumors (Ph1 SEASTAR study).

Cite

CITATION STYLE

APA

Yap, T. A., Hamilton, E., Bauer, T., Dumbrava, E. E., Jeselsohn, R., Enke, A., … Shapiro, G. I. (2022). Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precision Oncology, (6). https://doi.org/10.1200/po.21.00456

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Abstract

Cite

Register to see more suggestions